Announcements
Sidley Represents Nektar Therapeutics in Its Sale of Its Manufacturing Facility and Reagent Supply Business
November 4, 2024
Sidley is representing Nektar Therapeutics in its US$90 million sale of its manufacturing facility and reagent supply business to Ampersand Capital Partners. The sale will help to streamline Nektar Therapeutics’ future operations as it looks to expand its development of core research and development programs in immunology.
The Sidley team is being led by Daniel J. Belke and Tommy Tsao (M&A and Private Equity) and Joshua T. Hofheimer and Lauren G. Grau (Technology and Life Sciences Transactions), and includes Antoinette R. Petkov and Lauren E. Dunn (M&A and Private Equity) and Sabrina K. Glavota (Technology and Life Sciences Transactions).
Contacts
Capabilities
Suggested News & Insights
German Federal Court of Justice Strengthens Enforceability of Call Options in Management Equity ProgramsMarch 12, 2026Sidley Advises Verdane in Its Partnership With SmartboxMarch 12, 2026Sidley Represents The Western Union Company in US$450 Million Senior Notes OfferingMarch 11, 2026Sidley Represents Siris in Its Agreement to Acquire a Majority Stake in TAKKIONMarch 10, 2026Sidley Matter Shortlisted at Latin Lawyer’s 2026 Deal of the Year AwardsMarch 9, 2026Sidley Advises Forward Industries on Redomiciliation to TexasMarch 6, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory